Cargando…

Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study

INTRODUCTION: Many commercially available glucagon products for treatment of severe hypoglycaemia require cumbersome reconstitution and potentially intimidating injection during an emergency. Nasal glucagon (NG) is a novel drug-device combination product consisting of a single-use dosing device that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suico, Jeffrey G., Hövelmann, Ulrike, Zhang, Shuyu, Shen, Tong, Bergman, Brandon, Sherr, Jennifer, Zijlstra, Eric, Frier, Brian M., Plum-Mörschel, Leona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324463/ https://www.ncbi.nlm.nih.gov/pubmed/32514794 http://dx.doi.org/10.1007/s13300-020-00845-7

Ejemplares similares

Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
por: Pieber, Thomas R., et al.
Publicado: (2021)

The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects
por: Halberg, Inge B., et al.
Publicado: (2019)

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
por: Sherr, Jennifer L., et al.
Publicado: (2016)

Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon
por: Thieu, Vivian T., et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus
por: Plum-Mörschel, Leona, et al.
Publicado: (2023)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
por: Linnebjerg, Helle, et al.
Publicado: (2020)

New uses and formulations of glucagon for hypoglycaemia
por: Beato-Víbora, Pilar I, et al.
Publicado: (2019)

Nasal glucagon as a viable alternative for treating insulin‐induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study
por: Matsuhisa, Munehide, et al.
Publicado: (2020)

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting
por: Seaquist, Elizabeth R., et al.
Publicado: (2018)

Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia
por: Kristensen, Peter L, et al.
Publicado: (2016)

Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
por: Bianzano, Susanna, et al.
Publicado: (2022)

Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus
por: Hövelmann, Ulrike, et al.
Publicado: (2018)

Injecting without pressing a button: An exploratory study of a shield‐triggered injection mechanism
por: Zijlstra, Eric, et al.
Publicado: (2018)

Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study
por: Sha, S., et al.
Publicado: (2015)

Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
por: Frier, Brian M., et al.
Publicado: (2019)

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
por: Polidori, David, et al.
Publicado: (2013)

Nasal Bridge Intramuscular Hemangioma
por: Hamir Basah, Zulkifli, et al.
Publicado: (2015)

Hypoglycaemia in adults with insulin‐treated diabetes in the UK: self‐reported frequency and effects
por: Frier, B. M., et al.
Publicado: (2015)

Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources
por: Heller, S. R., et al.
Publicado: (2015)

Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data
por: Andersen, Grit, et al.
Publicado: (2020)

Cognitive deficits associated with impaired awareness of hypoglycaemia in type 1 diabetes
por: Hansen, Tor I., et al.
Publicado: (2017)

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study
por: Yale, Jean-François, et al.
Publicado: (2017)

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
por: Rickels, Michael R., et al.
Publicado: (2016)

Hypoglycæmia
Publicado: (1934)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study
por: Plum‐Mörschel, Leona, et al.
Publicado: (2022)

Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8
por: Harris, Cynthia, et al.
Publicado: (2017)

Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study
por: Kazda, Christof, et al.
Publicado: (2021)

Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial
por: Guzman, Cristina B., et al.
Publicado: (2017)

The Intramuscular Versus the Intrathecal Route in the Treatment of Tetanus by the Injection of Antitoxin
Publicado: (1918)

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
por: Flint, Anne, et al.
Publicado: (2021)

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
por: Signorovitch, J E, et al.
Publicado: (2013)

Insulin Hypoglycæmia
Publicado: (1948)

The consequences of hypoglycaemia
por: Amiel, Stephanie A.
Publicado: (2021)

Usability of Nasal Glucagon Device: Partially Randomized Caregiver and Third-Party User Experience Trial with Simulated Administration at a Japanese Site
por: Aranishi, Toshihiko, et al.
Publicado: (2019)

Pancreatic alpha cell-selective deletion of Tcf7l2 impairs glucagon secretion and counter-regulatory responses to hypoglycaemia in mice
por: da Silva Xavier, Gabriela, et al.
Publicado: (2017)

Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial
por: Gejl, Michael, et al.
Publicado: (2017)

EXPERIMENTS ON THE NASAL ROUTE OF INFECTION IN POLIOMYELITIS
por: Flexner, Simon, et al.
Publicado: (1920)

Hypoglycaemia in adrenal insufficiency
por: Lee, Shien Chen, et al.
Publicado: (2023)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n6oqdhst9ao9i2l66clt42rkdp